10-Q: TherapeuticsMD Reports Second Quarter 2024 Results, Transitioning to Royalty-Based Model

TherapeuticsMD's second quarter results show a net loss of $1.09 million as the company continues its transition to a pharmaceutical royalty business.

Summary

• TherapeuticsMD reported a net loss of $1.09 million for the second quarter of 2024, compared to a net loss of $2.414 million for the same period in 2023.
• The company's revenue for the quarter was $234 thousand, a decrease from $437 thousand in the second quarter of 2023, primarily due to changes in sales of licensed products.
• Operating expenses decreased to $2.674 million from $2.909 million year-over-year, reflecting cost reductions from the transition to a royalty-based business.
• The company recognized an impairment loss of $1.261 million related to abandoned patents and applications.
• TherapeuticsMD's primary revenue source is now royalties from licensed products, following the sale of its commercial operations to Mayne Pharma in December 2022.
• The company is currently in a dispute with Mayne Pharma regarding the calculation of allowances for payer rebates and wholesale distributor fees.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months due to potential liquidity issues.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including declining revenue, patent impairments, a dispute with a key partner, and a going concern warning. While cost-cutting measures are positive, the overall outlook is negative.

Positives

• The net loss decreased significantly year-over-year, indicating progress in cost management.
• Operating expenses have been reduced due to the transition to a royalty-based business model.
• The company received a one-time payment of $1.25 million from a sublessee.
• The company has $5.232 million in cash and cash equivalents.

Negatives

• License and service revenue decreased by 46.5% year-over-year.
• The company recorded a $1.261 million impairment loss on patents.
• There is a dispute with Mayne Pharma regarding working capital adjustments.
• The company's ability to continue as a going concern is in doubt due to potential liquidity issues.

Risks

• The company may need to raise additional capital to fund operations.
• The dispute with Mayne Pharma over working capital adjustments could negatively impact financials.
• If Mayne Pharma's sales of licensed products are lower than expected, royalty revenue will be impacted.
• The company's existing cash reserves may be insufficient to meet liquidity requirements.
• The company is dependent on third-party contract manufacturers and supply chain issues could impact revenue.

Future Outlook

The company may need to raise additional capital to fund operations and is working to resolve a dispute with Mayne Pharma regarding working capital adjustments. The company's future performance is dependent on the sales of licensed products by its partners.

Management Comments

• Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.
• Management believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable.

Industry Context

The shift to a royalty-based model is a significant change for TherapeuticsMD, reflecting a move away from direct commercial operations. This is not uncommon for smaller pharmaceutical companies that seek to monetize their intellectual property without the high costs of commercialization. The company's success is now heavily reliant on the commercial performance of its licensees.

Comparison to Industry Standards

• TherapeuticsMD's transition to a royalty-based model is similar to other pharmaceutical companies that have divested their commercial operations to focus on research and development or intellectual property management.
• The company's revenue is now dependent on the sales performance of its licensees, which is a common model in the pharmaceutical industry.
• The dispute with Mayne Pharma over working capital adjustments is not uncommon in large transactions and highlights the complexities of such deals.
• The company's cash position of $5.232 million is relatively low for a publicly traded pharmaceutical company, raising concerns about its ability to fund operations.

Management Changes

Legal Proceedings

• The company is involved in patent litigation with Teva Pharmaceuticals USA, Inc. regarding IMVEXXY.
• The company and Mayne Pharma filed a complaint for patent infringement against Sun Pharma Inc. regarding IMVEXXY.

Related Party Transactions

• The company has entered into subscription agreements with Rubric Capital Management LP, a related party.
• A director of the company, Mr. Justin Roberts, is a Partner of Rubric Capital Management LP.

Stakeholder Impact

• Shareholders face potential dilution if the company raises additional capital through equity offerings.
• Employees are limited to one full-time employee, with external consultants supporting operations.
• Customers are now served by Mayne Pharma, which has licensed the company's products.
• Suppliers are impacted by the company's transition to a royalty-based model.
• Creditors face increased risk due to the company's going concern warning.

Next Steps

• The company intends to resolve the dispute with Mayne Pharma through the dispute resolution process outlined in the Transaction Agreement.
• The company will continue to monitor the net working capital items related to the Mayne Pharma transaction.
• The company may pursue various equity and debt financing alternatives to address its capital needs.

Key Dates

Keywords

royalty, pharmaceutical, licensing, IMVEXXY, BIJUVA, ANNOVERA, Mayne Pharma, financial results, patent impairment, going concern